Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11750711 | 0.81 | ENPP2 (0.78) | SMN1; SMN2NPC1RAB9AENPP2HTT | |
| SCHEMBL1554384 | 0.81 | GRIN2B (0.71) | SMN1; SMN2NPC1RAB9AENPP2HTT | |
| SCHEMBL2476561 | 0.81 | ENPP2 (0.70) | SMN1; SMN2NPC1RAB9AENPP2HTT | |
| SCHEMBL3533651 | 0.77 | SMN1; SMN2 (0.77) | SMN1; SMN2NPC1RAB9AENPP2HTT | |
| SCHEMBL2712060 | 0.77 | SMN1; SMN2 (0.77) | SMN1; SMN2NPC1RAB9AENPP2HTT | |
| SCHEMBL6535871 | 0.76 | ENPP2 (0.62) | SMN1; SMN2NPC1RAB9AENPP2HTT | |
| SCHEMBL5347264 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AENPP2HTT | |
| SCHEMBL5355496 | 0.76 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AENPP2HTT | |
| SCHEMBL2306241 | 0.76 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AENPP2HTT | |
| SCHEMBL2466458 | 0.76 | ENPP2 (0.61) | SMN1; SMN2NPC1RAB9AENPP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927534-B2 | Compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-1979342-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jerini AG (DE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | ITGA1, ITGB1, ITGA5 | SMN1; SMN2 4197/4885NPC1 4203/4885RAB9A 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.